Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06039384 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Start date: December 28, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.

NCT ID: NCT06038396 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors

Start date: August 3, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

In Phase I, This study will explore the tolerability and safety of RC118 in combination with toripalimab for treatment of patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 in combination with toripalimab at RP2D doses for patients with different tumor types.

NCT ID: NCT06037317 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, single-arm, multicenter, phase Ib study to evaluate the efficacy and safety of SY-3505 capsule in patients with locally advanced or metastatic, LTK fusion-positive solid tumor who have progressed on or are intolerant to prior standard therapy.

NCT ID: NCT06036121 Recruiting - Solid Tumors Clinical Trials

A Study of ADRX-0706 in Select Advanced Solid Tumors

Start date: September 26, 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.

NCT ID: NCT06035744 Recruiting - Clinical trials for Advanced Solid Tumor

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Start date: December 12, 2023
Phase: Phase 1
Study type: Interventional

CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors

NCT ID: NCT06034470 Recruiting - Clinical trials for Acute Myeloid Leukemia

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Start date: December 18, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial finds the best dose of PVEK when given together with fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, (FLAG-Ida) regimen and studies the effectiveness of this combination therapy in treating patients with newly diagnosed adverse risk acute myeloid leukemia (AML) and other high-grade myeloid neoplasms. PVEK is a monoclonal antibody linked to a chemotherapy drug. PVEK is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD123 receptors, and delivers the chemotherapy drug to kill them. Chemotherapy drugs, such as idarubicin, fludarabine, high-dose cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. G-CSF helps the bone marrow make more white blood cells in patients with low white blood cell count due to cancer treatment. Giving PVEK with the FLAG-Ida regimen may be a safe and effective treatment for patients with acute myeloid leukemia and other high-grade myeloid neoplasms.

NCT ID: NCT06034275 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Start date: September 13, 2023
Phase: Phase 1
Study type: Interventional

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

NCT ID: NCT06034002 Recruiting - Clinical trials for Myeloproliferative Neoplasms

A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms

Start date: December 4, 2023
Phase: Phase 1
Study type: Interventional

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.

NCT ID: NCT06033976 Recruiting - Clinical trials for Neoplasm, Colorectal

Endoscopic Submucosal Dissection Registry

ESDREG
Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.

NCT ID: NCT06032845 Recruiting - Solid Tumor, Adult Clinical Trials

Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)

CASTLE-11
Start date: September 13, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib for patients with previously treated solid tumors.